09:11 AM EDT, 07/16/2025 (MT Newswires) -- Johnson & Johnson ( JNJ ) raised its full-year outlook on Wednesday as the healthcare products conglomerate recorded better-than-expected second-quarter results, amid double-digit gains from sales of its oncology and cardiovascular products.

The company now expects adjusted earnings to come in between $10.80 and $10.90 per share for 2025, up from its previous projections of $10.50 to $10.70. Sales, excluding the firm's COVID-19 vaccine, are pegged at $93.2 billion to $93.6 billion, up from the prior guidance of $91 billion to $91.8 billion.

The current consensus on FactSet is for non-GAAP EPS of $10.64 and sales of $91.42 billion for the current year. Johnson & Johnson's ( JNJ ) shares were up 2.2% in the most recent premarket activity.

For the quarter ended June, the company's adjusted EPS declined to $2.77 from $2.82 the year before, but topped the Street's view for $2.68. Sales improved 5.8% to $23.74 billion, ahead of the average analyst estimate of $22.85 billion. Operational sales, which exclude the impact of translational currency, rose 4.6% year over year, the firm said.

"Today's strong results reflect the depth and strength of Johnson & Johnson's ( JNJ ) uniquely diversified business operating across both MedTech and innovative medicine," Chief Executive Joaquin Duato said in the earnings release. "Our portfolio and pipeline position us for elevated growth in the second half of the year."

Medtech revenue inclined 7.3% to $8.54 billion, while the segment's operational sales climbed 6.1% with net acquisitions and divestitures boosting growth by 2%. Gains were mainly driven by the company's electrophysiology products, closure products from the general surgery division and from cardiovascular medical technology provider Abiomed, which saw global sales move 18% higher, according to Johnson & Johnson ( JNJ ).

Innovative medicine sales rose 4.9% to $15.2 billion. Operational revenue advanced 3.8% driven by oncology products including blood cancer therapy Darzalex and prostate cancer medication Erleada, among others. Darzalex and Erleada recorded increases of about 23% each in worldwide revenue.

Revenue in the US climbed to $13.54 billion from $12.57 billion in the prior-year quarter, while international sales were up 3.2% to $10.2 billion. Selling, marketing and administrative expenses rose to $5.89 billion from $5.68 billion last year.